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Risk factors, medical therapies and perioperative
events in limb salvage surgery: Observations from
the PREVENT III multicenter trial
Michael S. Conte, MD,a Dennis F. Bandyk, MD,b Alexander W. Clowes, MD,c Gregory L. Moneta,
MD,d Hamid Namini, PhD,e and Lynn Seely, MD,e Boston, Mass; Tampa, Fla; Seattle, Wash; Portland, Ore;
and South San Francisco, Calif
Objectives: Patients who require infrainguinal revascularization for critical limb ischemia (CLI) are at elevated risk for
cardiovascular events. The PREVENT III study was a prospective, randomized, multicenter, phase 3 trial of edifoligide
for the prevention of vein graft failure in patients with CLI. We examined the baseline characteristics, perioperative
medical therapies, and 30-day incidence of major cardiovascular events in the PREVENT III cohort.
Methods: Demographics, medical and surgical history, mode of presentation for the index limb, procedural details, and
concomitant medications were reviewed for all patients enrolled in PREVENT III (N  1,404). Major adverse
cardiovascular events, including death, myocardial infarction, or cerebrovascular event (stroke or transient ischemic
attack) were tabulated. Univariate and multivariate analyses were performed to discern factors that were associated with
the utilization of medical therapies and with perioperative events.
Results: Demographics and comorbidities reflected a population with diffuse, advanced atherosclerosis. Perioperative
mortality was 2.7%, and major morbidity included myocardial infarction in 4.7% and stroke/transient ischemic attack in
1.4%. Among this population of CLI patients, 33% were not on antiplatelet therapy at study entry, and 24% were not
receiving antithrombotics of any type. In addition, 54% of patients were not receiving lipid-lowering therapy, and 52%
were not prescribed -blocker medications at study entry. On multivariate analysis, race was a significant determinant of
antithrombotic utilization, with African-American patients less frequently treated both at baseline and discharge
(adjusted odd ratios, 0.5 and 0.6, P < .0001). Antithrombotic and -blocker drug usage increased in the overall cohort
from baseline (76% and 48%) to discharge (88% and 60%; P< .0001). Patients treated in a university hospital setting were
more likely to be prescribed antiplatelet, lipid-lowering, and -blocker medications. Advanced age (>75 years), coronary
artery disease (prior myocardial infarction or revascularization), and dialysis-dependent renal failure were associated with
an increased 30-day risk of death, myocardial infarction, or stroke. Protective effects of -blocker and lipid-lowering
medications were noted in these defined subgroups.
Conclusions:A significant percentage of the population that undergoes surgical revascularization for CLI is not prescribed
therapies of proven benefit in reducing cardiovascular events. Utilization of antithrombotics and -blockers increases
during hospitalization for limb salvage surgery but that of lipid-lowering therapy does not. African-American patients
appear to be at greater risk for undertreatment with antithrombotics, and the data suggest that patients undergoing leg
bypass surgery in a university hospital setting receive more comprehensive medical treatment of atherosclerosis.
Treatment guidelines for medical therapy are needed to standardize care and improve outcomes for patients with CLI.
(J Vasc Surg 2005;42:456-65.)Peripheral arterial disease (PAD), a common manifes-
tation of atherosclerosis, afflicts an estimated 5 to 12 mil-
lion Americans.1,2 Critical limb ischemia (CLI) represents
the most advanced stage of PAD and is associated with high
rates of cardiovascular mortality, morbidity, diminished
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456quality of life, and major limb amputation.3 Several studies
have demonstrated that PAD in general, and CLI in partic-
ular, portend a cardiovascular event risk that is at least
equivalent to that of patients with symptomatic coronary
artery disease (CAD).4-7 Treatment of patients with CLI
thus focuses on the relief of ischemic limb symptoms,
avoidance of amputation, and aggressive management of
the underlying atherosclerosis to reduce overall mortality
and morbidity. Despite the frequency and severity of CLI,
established treatment guidelines do not exist, and a broad
range of medical, surgical, and interventional therapeutic
approaches are used.
Infrainguinal arterial reconstruction with autogenous
vein bypass is a commonly used and effective treatment for
limb salvage; however, the efficacy of this procedure is
limited by failure rates that may reach as high as 50% within
5 years.8 The PRoject of Ex-Vivo vein graft ENgineering
via Transfection III (PREVENT III) study was a prospec-
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trial of a novel molecular therapy (edifoligide) for the
prevention of vein graft failure in patients undergoing
surgical bypass for CLI. This trial, with a randomized
population of 1,400 patients from both community and
university hospital settings, represents a unique opportu-
nity for a broad examination of the current state of surgical
and medical treatment for CLI.
Medical therapy for atherosclerosis has improved con-
siderably over the past two decades with the advent of
powerful antithrombotic, antihypertensive, and lipid-low-
ering drugs. In addition to their overall impact on cardio-
vascular mortality and morbidity, several of these drug
classes have been associated with improved outcome in
PAD patients, including beneficial effects on bypass graft
patency. We sought to examine the use of medical therapies
in the PREVENT III cohort and to determine factors
associated with prescribing patterns in the setting of hospi-
talization for lower extremity bypass. We also examined the
incidence of major adverse perioperative events (death,
myocardial infarction, stroke) and their relationship to co-
morbid factors and medical therapies within the study
population.
METHODS
PREVENT III trial design. PREVENT III was a
multicenter, double-blinded, randomized, placebo-con-
trolled trial of edifoligide for the prevention of vein graft
failure in patients undergoing lower extremity bypass for
the treatment of CLI. The trial was co-sponsored by Cor-
gentech, Inc (South San Francisco, CA) and Bristol-Myers
Squibb (Princeton, NJ). Details of the trial design are
reported elsewhere9 and are briefly summarized here. The
trial randomized 1,404 patients at 83 participating sites (62
university-based, 21 non university-based hospitals) in the
United States and Canada. Enrollment was initiated in
November 2001 and completed in September 2003. Pa-
tients were to be 18 years of age and present with symp-
toms of CLI, including gangrene, a nonhealing ischemic
ulcer, or rest pain. The primary end point of the study was
the time to occurrence of nontechnical graft failure result-
ing in either graft revision or major amputation (ie, tran-
stibial or above) within 12 months of enrollment.
Investigators were allowed to use any and all appropri-
ate concomitant medications, both before and after the
procedure, as dictated by their usual clinical practice pat-
terns. The protocol discouraged the use of postoperative
anticoagulant drugs for the sole indication of prevention of
bypass graft occlusion.
Baseline data collected and definitions. A detailed
history and physical examination were performed on all
patients at study entry. Comorbid conditions were charac-
terized from the patient’s interview or prior medical
records. These included a history of advanced CAD, de-
fined here as a prior history of myocardial infarction, coro-
nary artery bypass grafting, or percutaneous coronary inter-
vention; symptomatic cerebrovascular disease (CVD),
defined as a prior stroke or transient ischemic attack; dia-betes mellitus; hypertension; hyperlipidemia; renal failure;
prior lower extremity arterial reconstruction, including
prior infrainguinal bypass graft (IBG); chronic obstructive
pulmonary disease; and smoking status.
Trial sites were categorized as university hospitals if
they had accredited residency programs and medical stu-
dent clerkships. Data were collected on concomitant med-
ications used at baseline and at discharge from the index
hospitalization by using forms with check boxes for specific
medications. Antiplatelet therapy included treatment with
aspirin or a thienopyridine. Antithrombotic therapy in-
cluded treatment with antiplatelet therapy or with low-
molecular-weight heparin or an oral anticoagulant.
Statistical methods. Univariate statistical associations
between the use of antiplatelet, anticoagulant, antithrom-
botic, -blocker, and lipid-lowering medications and pa-
tients’ demographic and comorbid characteristics were as-
sessed. The factors examined included age, gender, race,
hospital setting (university-affiliated or not), CAD, CVD,
diabetes mellitus, prior IBG, renal failure requiring dialysis,
smoking, hyperlipidemia, and hypertension. Univariate sta-
tistical associations between the first 30-day composite
adverse event of death, myocardial infarction, or stroke and
the use of each class of medications, demographics, and
comorbid characteristics were assessed. The Pearson 2 test
was used to assess the univariate associations.
Univariate analyses of a shift in proportion of patients’
usage of the therapies from baseline to the time of hospital
discharge were performed with the McNemar test.
Upon completion of the univariate analyses, factors
that were significantly associated (P  .10) with drug class
utilization or the 30-day composite adverse events were
selected for multivariate analyses. The multivariate analysis
statistically adjusts the estimated effects of each baseline
factor in the model for differences in the distributions of
and associations among the other baseline factors. Gener-
alized estimating equations using logistic link were used to
conduct themultivariate analyses. Themodel for utilization
of the medications at baseline and at the time of discharge
was constructed such that it accounted for the intrapatient
correlation between baseline and time of hospital dis-
charge. The statistical significance of each factor in the
model was assessed by using the Wald test.
RESULTS
Baseline characteristics of the PREVENT III study
population. The demographics and comorbidities of the
patients enrolled in PREVENT III reflect those of a popu-
lation with diffuse, advanced atherosclerosis (Table I).
Most of the patients were male (64%), with a mean  SD
age of 69  12 years, and 33% were 75 years old. Nearly
two thirds (64%) had diabetes mellitus, 74% were smokers,
82% hypertensive, and 55% had a prior diagnosis of hyper-
lipidemia. Forty-six percent had a history of advanced
CAD, as defined by previous myocardial infarction in 30%,
previous coronary artery bypass in 25%, and previous per-
cutaneous coronary intervention in 17%. Twenty percent of
patients had a history of stroke or transient ischemic attack
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present in 12% of patients at study entry.
Previous lower extremity bypass surgery had been per-
formed in 25% of patients, 11% in the limb contralateral to
the index graft. Seventy-five percent of patients presented
with tissue loss (39% ulcer, 36% gangrene) as the primary
manifestation of CLI necessitating lower extremity bypass
surgery. Diabetic patients were more likely to present with
tissue loss (86% vs 56%; P  .0001) as the indication for
revascularization.
The racial breakdown of the study cohort was 72.4%
Caucasian, 17.7% African American (AA), 7.6% Hispanic,
0.7% Asian, and 1.5% other. AA patients were younger than
Caucasian and other racial groups combined (mean  SE
age, 66  0.7 vs 70  0.3 years; P  .0001) and were more
commonly female (47% vs 34%; P  .0001). AA patients
had a lower prevalence of previous CAD (37% vs 51%; P 
.0001), hyperlipidemia (45% vs 57%; P  .0003), and prior
IBG (19% vs 29%; P  .001), as well as a greater incidence
of hypertension (88% vs 80%; P  .0045) and dialysis-
dependent renal failure (21% vs 10%; P  .0001) than their
non-AA counterparts. Diabetes, CVD, smoking status, and
mode of presentation of the index limb were similar with
regard to race.
Use of medical therapies at baseline. Antiplatelet
drugs were being taken by 67% of the patients at study
entry, including aspirin in 50% and thienopyridine drugs in
17%. Anticoagulant drugs were being taken by 20% of
patients at baseline. At the time of entry into PREVENT
Table I. Descriptive characteristics of the PREVENT III
cohort
% of total
(n  1,404)
Age (mean  SD) 69  12 yrs
Male gender 64
Race/ethnicity
Caucasian 72.4
African-American 17.7
Hispanic 7.6
Asian 0.7
Other 1.5
Smoking 74
Diabetes mellitus 64
Insulin-dependent 34
Hypertension 82
CAD 48
Prior MI 30
Prior CABG 25
Prior PCI 17
CVD 20
Hyperlipidemia 55
Prior IBG 27
Dialysis-dependent 12
PREVENT, Prevention of Recurrent Venous Thromboembolism; CAD,
coronary artery disease; MI, myocardial infarction; CABG, coronary artery
bypass graft; PCI, percutaneous coronary intervention; CVD, cerebrovascu-
lar disease, either stroke or transient ischemic attack; IBG, infrainguinal
bypass graft of either extremity.IIII, 76% of patients were taking an antithrombotic.Twenty percent of patients with a history of IBG surgery,
13% of those with CAD, and 16% of those with CVD were
not taking antithrombotic medications at trial entry.
Univariate analysis of factors related to antithrombotic
drug use at baseline revealed a significant positive associa-
tion with male gender (P  .0251), CAD (P  .0001),
CVD (P  .0006), hyperlipidemia (P  .0001), and prior
IBG (P  .0171). AA race was negatively associated with
antithrombotic drug use at baseline (63% vs 79% Cauca-
sian/other, P  .0001). On multivariate analysis, CAD
(odds ratio [OR], 2.5; 95% confidence interval [CI], 1.9 to
3.3; P  .0001), CVD (OR, 1.7; 95% CI, 1.2 to 2.4; P 
.0054), and hyperlipidemia (OR, 1.6; 95% CI, 1.2 to 2.1; P
 .0006) remained positively associated with antithrom-
botic usage at baseline (Fig 1, A). In contrast, AA race
remained negatively associated (OR, 0.5; 95% CI, 0.4 to
0.7; P  .0001) with antithrombotic therapy in the multi-
variate model. These associations were quite similar for the
subcategory of antiplatelet drugs at entry. For anticoagu-
lants considered alone, male gender (OR, 1.3; 95% CI,
1.003 to 1.8; P .0479) and prior IBG (OR, 1.9; 95% CI,
1.4 to 2.5; P  .0001) were positively associated with and
AA race (OR, 0.6; 95% CI, 0.4 to 0.9; P  .0170) was
negatively associated with usage in themultivariate analysis.
Lipid-lowering drugs were being taken by 46% of pa-
tients at baseline. Of those patients with a stated history of
hyperlipidemia, 25% were not on any apparent drug ther-
apy. Forty-one percent of patients with a significant CAD
history, 48% of those with prior CVD, and 44% of those
with prior IBG were not receiving lipid-lowering drugs.
On univariate analysis, university hospital setting (P 
.0193), prior CAD (P  .0001), diabetes mellitus (P 
.0001), IBG (P .0001), hypertension (P .0001), CVD
(P  .0302), and a history of hyperlipidemia (P  .0001)
were positively associated, whereas AA race (P  .0002)
was negatively associated with the use of lipid-lowering
drugs. When multivariate modeling was used, hyperlipid-
emia (OR, 23.3; 95% CI, 17.1 to 31.8; P  .0001), CAD
(OR, 1.8; 95% CI, 1.4 to 2.5; P .0001), diabetes mellitus
(OR, 1.4; 95% CI, 1.1 to 1.9; P  .0215), and IBG (OR,
1.4; 95% CI, 1.02 to 1.9; P  .0372) remained as signifi-
cant predictors of utilization of lipid-lowering medications
at trial entry (Fig 1, B).
At trial entry, 49% of patients were being prescribed
-blocker medications. Factors positively associated with
-blocker use on univariate analysis included university
hospital setting (P .0001), CAD (P .0001), CVD (P
.0017), diabetes mellitus (P  .0001), hypertension (P 
.0001), and hyperlipidemia (P  .0001); smoking (P 
.0172) was negatively associated.
Multivariate analysis confirmed a positive association
with university hospital (OR, 1.9; 95% CI, 1.5 to 2.4; P 
.0001), CAD (OR, 2.3; 95% CI, 1.8 to 2.9; P  .0001),
hypertension (OR, 2.6; 95% CI, 1.9 to 3.6; P  .0001),
and hyperlipidemia (OR, 1.5; 95% CI, 1.2 to 1.9; P 
.0010). The negative association with smoking remained
(OR, 0.7; 95% CI, 0.6 to 1; P  .0186) (Fig 1, C).
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Volume 42, Number 3 Conte et al 459Fig 1. Factors associated with the utilization of (A) antithrombotic, (B) lipid-lowering, and (C) -blocker medica-
tions in the PREVENT III patient cohort at trial entry. Odds ratios (OR) and 95% confidence intervals (CI) are shown
for all factors that reached significance (P  .05) in the multivariate model. CVD, Cerebrovascular disease; CAD,
coronary artery disease; AA, African-American; IBG, infrainguinal bypass graft; HTN, hypertension.
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tions in the PREVENT III patient cohort at discharge after adjusting for baseline usage. Odds ratios (OR) and 95%
confidence intervals (CI) are shown for all factors that reached significance (P .05) in the multivariate model. CVD,
Cerebrovascular disease; CAD, coronary artery disease; AA, African-American; IBG, infrainguinal bypass graft; HTN,
hypertension.
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Across the overall study cohort, the use of antithrombotic
drugs significantly increased from 75% at baseline to 88% at
hospital discharge (P .0001). This trend was observed in
both the antiplatelet (67% vs 80%; P  .0001) and antico-
agulant (20% vs 27%; P  .0001) drug categories individ-
ually. Rates of -blocker use also increased from 48% at
baseline to 60% at discharge (P  .0001). In contrast,
lipid-lowering drug use did not change appreciably from
baseline (46%) to discharge (46%) (Fig 3).
A multivariate analysis was used to evaluate factors
associated with drug use at discharge, taking into account
the intrapatient correlation over time in the model. For
antithrombotic drugs (Fig 2, A), CAD (OR, 2.3; 95% CI,
1.8 to 2.9; P .0001), CVD (OR, 1.6; 95% CI, 1.1 to 2.2;
P  .0070), and hyperlipidemia (OR, 1.5; 95% CI, 1.1 to
1.9; P  .0023) were positively associated with use at
hospital discharge. In contrast, AA race had a negative
association (OR, 0.6; 95% CI, 0.4 to 0.8; P  .0001) with
the use of antithrombotic medication at discharge, al-
though the overall use in AA patients did increase from 63%
at baseline to 81% at discharge.
In examining the subcategory of antiplatelet drugs at
discharge, university hospital setting (OR, 1.5; 95% CI, 1.2
to 1.8; P .0005), CAD (OR, 2.0; 95% CI, 1.6 to 2.5 P
.0001), CVD (OR, 1.4; 95% CI, 1.03 to 1.8; P  .0288),
and hyperlipidemia (OR, 1.3; 95% CI, 1.1 to 1.7; P 
Fig 3. Summary of changes in utilization of medications during
the index hospitalization for lower extremity bypass surgery. *In-
dicates statistically significant shift in utilization between baseline
and discharge..0106) were positively associated with antiplatelet usage;AA race was a negative predictor (OR, 0.7; 95% CI, 0.5 to
0.9; P  .0089).
Anticoagulant use at discharge was positively associated
with a prior IBG (OR, 1.8; 95% CI, 1.4 to 2.3; P .0001),
university hospital (OR, 1.3; 95% CI, 1.02 to 1.7; P 
.0331), CAD (OR, 1.3; 95% CI, 1.04 to 1.7; P  .0200)
and negatively associated with diabetes mellitus (OR, 0.6;
95% CI, 0.5 to 0.8; P  .0002).
For lipid-lowering drugs, there was little change in the
factors associated with drug use from baseline to discharge.
At discharge, hyperlipidemia (OR, 19.1; 95% CI, 14.3 to
25.4; P .0001), CAD (OR, 1.7; 95% CI, 1.3 to 2.2; P
.0002), prior IBG (OR, 1.4; 95% CI, 1.03 to 1.8; P 
.0332), university hospital setting (OR, 1.4; 95% CI, 1.044
to 1.8; P .0234), and diabetes mellitus (OR, 1.4; 95%CI,
1.06 to 1.8; P .0174) were positively associated with the
use of lipid-lowering medications (Fig 2, B).
Multivariate modeling of -blocker use at discharge
revealed positive associations with university hospital set-
ting (OR, 2.4; 95% CI, 2 to 3.1; P  .0001), CAD (OR,
2.1; 95% CI, 1.7 to 2.6; P  .0001), hypertension (OR,
2.4; 95% CI, 1.8 to 3.1; P  .0001), and hyperlipidemia
(OR, 1.4; 95% CI, 1.1 to 1.7; P  .0068). Smoking
remained negatively associated (OR, 0.7; 95% CI, 0.6 to
0.9; P  .0169) with -blocker usage (Fig 2, C).
Major adverse perioperative events. Overall 30-day
mortality for the trial cohort was 38 patients (2.7%). Major
cardiovascular complications (Table II) included myocar-
dial infarction in 66 patients (4.7%) and stroke or transient
ischemic attack in 20 (1.4%). The composite outcome of
death, myocardial infarction, or CVA occurred in 113
patients (8%). Univariate positive associations with the
composite event outcome were found for CAD (P 
.0001), age75 years (P .0036), smoking (P .0179),
dialysis (P  .0238), diabetes mellitus (P  .0505), CVD
(P  .0811), and hypertension (P  .0866).
There was no apparent overall effect of antithrombotic
or lipid-lowering medications, and -blocker use had a
paradoxical positive association with events (P  .0111) in
the univariate analysis. Multivariate analysis revealed that
age75 (OR, 2.2 vs age 65 to 74; 95% CI, 1.3 to 3.5; P
Table II. Major adverse perioperative (30-day) events
N (% of total)
Death 38 (2.7)
Cardiac
Cardiopulmonary arrest 21 (1.5)
MI 66 (4.7)
Cerebrovascular (CVA)
Stroke/TIA 20 (1.4)
Venous thromboembolism
DVT 14 (1.0)
PE 1 (1.0)
Composite death/MI/CVA 113 (8)
MI, Myocardial infarction; TIA, transient ischemic attack; DVT, deep ve-
nous thrombosis; PE, pulmonary embolism..0022), CAD (OR, 2.3; 95% CI, 1.5 to 3.6; P  .0001),
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were independently associated with increased risk of the
composite adverse cardiovascular outcome.
Although significant associations of medications with
the composite adverse outcome could not be demonstrated
in the multivariate main effect model, important positive
two-way interactions were noted among these three clinical
factors and certain drugs at trial entry. Age and dialysis-
dependent renal failure demonstrated significant interac-
tions with lipid-lowering therapy. For patients75 years of
age, the adjusted OR of a perioperative event was 3.1 times
higher (95% CI, 1.5 to 6.2; P  .0019) in patients not on
lipid-lowering drugs versus those taking the medications.
Similarly, the adjustedOR for dialysis patients was 4.1 (95%
CI, 1.3 to 13; P  .0170) for those not on lipid-lowering
therapy. Among the group of patients who were not receiv-
ing -blocker drugs at study entry, the adjusted OR of an
event was 3.9 times higher (95% CI, 2.0 to 7.5; P .0001)
in those with a prior history of advanced CAD compared
with those without such a history.
DISCUSSION
The PREVENT III study is the largest prospective trial
conducted to date in patients undergoing lower extremity
vein bypass surgery in North America and reflects the
current epidemiology and practice trends relative to the
surgical treatment of advanced PAD. As expected, the
population of CLI patients enrolled in this study has a high
prevalence of comorbidities, reflective of diffuse and ad-
vanced systemic atherosclerosis. Despite the frequent pres-
ence of other recognized cardiovascular risk factors
amongst this cohort and the growing recognition of PAD
itself as a risk factor equivalent to CAD, a significant under-
utilization of standard medical therapies was observed.
Approximately one in four patients with CLI were not
receiving antithrombotic medications at baseline, andmore
than half did not receive -blocker or lipid-lowering ther-
apies. These observations, which are consistent with obser-
vations from other smaller series,10-12 attest to a critical
need for the development and implementation of treat-
ment guidelines for patients with PAD, and particularly
those with the most advanced clinical stage of CLI.
Recent reports have highlighted the fact that PAD is
underdiagnosed1 and undertreated10 compared with CAD,
although its presence portends similar long-term risks of
morbid cardiovascular events. The epidemiology of PAD,
which is strongly associated with age (14.5% prevalence in
the 70 age group)2 and diabetes mellitus (more than a
threefold increased risk)2, insures that its impact on the
health system will continue to grow. Compared with CAD,
PAD patients are older and are more commonly female,
African-American, diabetic, and smokers.2,10,13 With cur-
rent estimates of PAD prevalence in the United States
ranging from 5 to 12 million adults, the prevention and
treatment of its attendant complications is a significant
public health issue at present.
CLI occurs in a small fraction of the PAD population
and correlates with the most severe global atherosclerosisburden. Mortality rates observed in patients with CLI are
typically in the range of 20% by 1 year, with most deaths
related to cardiac causes. Patients with CLI whose extrem-
ity disease is untreated or who have an unreconstructable
anatomy can expect a 40% amputation rate within 6
months.3 Aggressive medical, interventional, and surgical
management is required to improve upon this dire natural
history.
Antiplatelet and antithrombotic medications are a cor-
nerstone of secondary prevention in atherosclerosis. Several
large cohort studies14,15 have documented that antiplatelet
therapy is associated with a reduction in cardiovascular
events in PAD patients. Potential benefits of antithrom-
botic therapy include improved patency of lower extremity
bypass grafts and a reduction in amputations.16-18 Al-
though the optimal antithrombotic regimen for patients
undergoing vein bypass graft surgery remains somewhat
controversial, the existing literature strongly supports at
least aspirin therapy for all patients without contraindica-
tions. Despite this preponderance of evidence, undertreat-
ment of PAD patients with these medications has been
documented in several studies1,10,11 and is corroborated in
the PREVENT III cohort.
Lipid-lowering drugs, particularly the 3-hydroxy-3-
methylglutaryl coenzyme A (HMG CoA) reductase inhib-
itors (statins), have demonstrated significant benefit in
numerous secondary prevention trials, again largely in pa-
tients with CAD.19-21 Recent evidence further suggests
that the target level of total cholesterol, as well as the
low-density lipoprotein fraction, in patients with clinical
evidence of cardiovascular disease is still undefined and
substantially lower than previous guidelines had suggest-
ed.20,21
Of particular relevance to the PAD population, the
recent Heart Protection Study21 examined the long-term
(5-year) effects of cholesterol-lowering therapy with a sta-
tin on vascular and nonvascular mortality and morbidity.
Patients with total cholesterol levels 135 mg/dL were
included if they had a significant clinical manifestation of
atherosclerosis, of which PAD alone was considered ade-
quate evidence. Treated patients demonstrated a 17% re-
duced incidence of cardiovascular-related death and
roughly a 25% reduction in myocardial infarction, coronary
revascularization, and stroke.
Statin therapy has also been associated with decreased
perioperative mortality in patients undergoing major vas-
cular surgery.22 A recent report has demonstrated an asso-
ciation between statin use and long-term survival after
abdominal aortic aneurysm repair.23
Finally, several recent reports have suggested that statin
use may be linked to improved patency of coronary24 and
lower extremity12,25 vein bypass grafts. This body of clinical
evidence is linked to a growing understanding of the mech-
anisms of the beneficial effects of statins on inflammation,
endothelial function, thrombosis, and intimal hyperpla-
sia.26,27
The -blocker class of medications has been established
as critical cardioprotective agents for patients undergoing
JOURNAL OF VASCULAR SURGERY
Volume 42, Number 3 Conte et al 463major vascular surgery and constitutes a cornerstone of
medical management of hypertension and CAD.28,29 In-
deed, the benefits of perioperative -blocker use in vascular
patients appear to extend well beyond the period of oper-
ative stress, with several studies documenting a long-term
benefit in the reduction of cardiovascular events and
death.30,31 Recent data further suggest that combination
therapy with statins and -blockers is associated with addi-
tional reductions in perioperative mortality and cardiac
events for patients undergoing elective aneurysm surgery.32
Chronic obstructive pulmonary disease is a relevant
potential contraindication to -blocker use that was not
prospectively captured in our database, although smoking
as a surrogate marker did demonstrate a negative associa-
tion with the use of these drugs. In the absence of more
solid information on the frequency of potential contraindi-
cations or drug interactions, we are unable to comment
further on the appropriateness of the utilization rate ob-
served in PREVENT III.
A salient finding of this study is that both race and
practice setting influenced the utilization of medical thera-
pies in the PREVENT III cohort. African-Americans are at
higher risk for PAD, diabetes mellitus, hypertension, and
renal failure.33-36 These factors, as well as a reduced access
to medical care, have been implicated in the elevated car-
diac mortality rate observed in the African-American pop-
ulation.
For all three of the drug categories examined, we
observed reduced rates of utilization in nonuniversity insti-
tutions. The differences were most dramatic in discharge
medications, suggesting that the aggressiveness of periop-
erative management, as opposed to variations in the popu-
lations treated among sites, was most likely responsible.
Some caution is required in interpretation of these findings,
because other potentially confounding variables, such as
socioeconomic status, costs, and insurance coverage, were
not included in the statistical model. Clearly, additional
studies would be required to confirm these findings and to
provide a greater understanding of the factors and pro-
cesses that determine drug utilization in the setting of
hospitalization for limb salvage surgery.
Finally, the data strongly suggest that in contrast to
antithrombotic and -blocker medications, lipid-lowering
therapies are generally not being considered during hospi-
talization for surgical revascularization of the ischemic
limb. Although cholesterol data are not available, it is
highly likely that most of the patients in PREVENT III
would have met the inclusion criteria for the Heart Protec-
tion Study, which was published during the early phase of
trial recruitment. More than a quarter of patients with a
prior diagnosis of hyperlipidemia were untreated at study
entry and were discharged in the same untreated state. As
already noted, the indications for the use of statin drugs in
patients with atherosclerosis continue to broaden on the
basis of solid clinical evidence, some of which suggests a
direct positive effect on the outcomes of bypass surgery.
The present data provide some additional evidence that
these medications may be cardioprotective in high-riskpopulations undergoing vascular reconstruction and sug-
gest that the awareness of surgeons may need to be in-
creased in this area.
This study has several noteworthy limitations. First the
diagnosis of comorbid conditions was made based on self-
reported patient history and the medical record. Diabetes
mellitus and hyperlipidemia were not substantiated by the
results of laboratory testing. Data on medications relate to
drugs prescribed and do not address patient compliance
with these regimens. The PREVENT III study was not
designed to examine the influence of concomitant medical
therapies on outcomes of limb salvage surgery. Patients
were treated according to standard local practice ap-
proaches at the individual participating institutions, and the
utilization of medications was clearly selective. As such, the
ability to discriminate the specific effects of cardioprotective
drugs on perioperative or long-term events is greatly lim-
ited. However, given the size of the cohort and the number
of sites, we believe this study provides a realistic represen-
tation of current practice in patients with CLI in North
America.
CONCLUSION
This study has potentially important implications for all
practitioners involved in the treatment of patients with
PAD and for vascular surgeons in particular. Prior studies
have demonstrated that PAD patients commonly identify
vascular surgeons as their primary physician.10
In the context of hospitalization for peripheral vascular
reconstruction, a critical opportunity exists to optimize the
management of all atherosclerosis risk factors. The data
strongly suggest that patients with CLI, who are among the
highest risk group for all cardiovascular complications, are
underprescribed antithrombotic, -blocker, and lipid-low-
ering therapies of demonstrated short- and long-term ben-
efit. For most such patients, clinical evidence indicates that
these medications should be part of a standard antiathero-
sclerosis regimen. Improved patient and physician aware-
ness, and the active promulgation of therapeutic guidelines,
are required to improve the global care of patients with
advanced PAD.
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Although vascular surgeons recognize that atherosclerosis is a
systemic disease, we are frequently reminded that our practical
application of this knowledge has been less than ideal. The current
article is no exception. The PREVENT III investigators enrolled
1404 patients with critical limb ischemia from 83 North American
centers in a prospective, randomized, multicenter trial of edifoli-
gide for the prevention of vein graft failure. With publication of
graft-related outcomes pending, this article examined the relation-pies, and the 30-day incidence of mortality, myocardial infarction,
and cerebrovascular events. There were no specific inclusion crite-
ria with respect to medical therapies; this allowed the authors to
examine the contemporary medical management of patients with
advanced lower extremity atherosclerotic disease.
Their findings are sobering, to say the least. Although one
fourth of patients had encountered a vascular surgeon previously
while undergoing lower extremity revascularization, one third
were not receiving antiplatelet agents, and half were not taking
